---
title: "Insights into Alkermes's Upcoming Earnings"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/276768593.md"
description: "Alkermes (NASDAQ:ALKS) is set to announce its quarterly earnings on February 25, 2026, with analysts estimating an EPS of $0.38. The company previously beat EPS estimates by $0.12, leading to a 1.45% share price increase. Currently, shares are trading at $32.19, down 3.88% over the past year, indicating bearish sentiment among long-term shareholders. Analysts emphasize the importance of guidance in stock price movements, and the consensus rating reflects cautious optimism ahead of the earnings release."
datetime: "2026-02-24T17:02:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276768593.md)
  - [en](https://longbridge.com/en/news/276768593.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276768593.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/276768593.md) | [English](https://longbridge.com/en/news/276768593.md)


# Insights into Alkermes's Upcoming Earnings

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Wednesday, 2026-02-25. Here's a quick overview of what investors should know before the release.

Analysts are estimating that Alkermes will report an **earnings per share** (EPS) of $0.38.

The announcement from Alkermes is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.

It's worth noting for new investors that guidance can be a key determinant of stock price movements.

### Performance in Previous Earnings

Last quarter the company beat EPS by $0.12, which was followed by a 1.45% increase in the share price the next day.

Here's a look at Alkermes's past performance and the resulting price change:

**Quarter**

**Q3 2025**

**Q2 2025**

**Q1 2025**

**Q4 2024**

**EPS Estimate**

0.37

0.34

0.24

0.76

**EPS Actual**

0.49

0.52

0.13

1.04

**Price Change %**

1.00

3.00

4.00

7.00

![eps graph](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771952541_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

### Performance of Alkermes Shares

Shares of Alkermes were trading at $32.19 as of February 23. Over the last 52-week period, shares are down 3.88%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

### Analysts' Take on Alkermes

For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Alkermes.

The consensus rating for Alkermes is , based on analyst ratings. With an average one-year price target of $, there's a potential .

To track all earnings releases for Alkermes visit their earnings calendar on our site.

_This article was generated by Benzinga's automated content engine and reviewed by an editor._

### 相關股票

- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [Alkermes (ALKS.US)](https://longbridge.com/zh-HK/quote/ALKS.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)

## 相關資訊與研究

- [Alkem Laboratories Gets Board Nod to Boost Investment in New Factory](https://longbridge.com/zh-HK/news/281495465.md)
- [TD Cowen Sticks to Their Buy Rating for Alkermes (ALKS)](https://longbridge.com/zh-HK/news/281419637.md)
- [Tritonpoint Wealth LLC Sells 10,771 Shares of Zoetis Inc. $ZTS](https://longbridge.com/zh-HK/news/281684930.md)
- [Canada's Perimeter Medical Imaging prelim Q4 revenue jumps 143%](https://longbridge.com/zh-HK/news/281240360.md)
- [Alar Breaks Key Barriers In Ketamine Therapy With Positive Phase 1 Results For Long-Acting Injectable Ala-3000 For Treatment-Resistant Depression](https://longbridge.com/zh-HK/news/281758743.md)